MedPath

Microbiome Sampling in GI Disease With a Focus on Small Intestinal Microbial Assessment

Not yet recruiting
Conditions
Healthy
IBS - Irritable Bowel Syndrome
Inflammatory Bowel Diseases
Registration Number
NCT06066866
Lead Sponsor
Stanford University
Brief Summary

GI disorders are influenced by the gut microbiome. To date, sampling of the small intestine in GI disorders has been limited. The investigators plan to sample the small intestinal contents during endoscopy for research purposes.

Detailed Description

Current guidelines (AGA Clinical Practice Update, 2020) report the definition of SIBO as a clinical entity lacks precision and consistency; it is a term generally applied to a clinical disorder where symptoms, clinical signs, and/or laboratory abnormalities are attributed to changes in the numbers of bacteria or in the composition of the bacterial population in the small intestine. To date, there is unlimited knowledge regarding the diagnostic criterion which has been limited by nonspecific and nonsensitive testing such as breath tests. Breath tests have a limited use in patients with IBS-D who inherently have increased gut transit time rendering the testing invalid for accurately measuring small intestinal bacteria. Additionally, the relationship between SIBO and symptoms in patients without obvious risk factors (such as anatomical changes due to surgery) is unknown. The investigators study aims to investigate the microbial landscape of the small intestine in healthy patients and those with GI disease (suspected or diagnosed) undergoing an upper endoscopy by collecting an aspirate of patient small intestinal fluid and studying it.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Age >18years
  • Patients seen at Stanford University Digestive Health Center who are scheduled for an upper endoscopy as part of their Standard Of Care
Exclusion Criteria

Children (under age 18years) Pregnant Women and Fetuses Neonates (0 - 28 days) Impaired Decision Making Capacity

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Ability to isolate live bacteria from 95% of samples1-4 years

We aim to isolate live bacteria from 95% of samples

Secondary Outcome Measures
NameTimeMethod
Ability to measure quantitative Colony Forming Units (CFUs) in 90% of samples1-4 years

We aim to measure quantitative Colony Forming Units (CFUs) in 90% of samples

© Copyright 2025. All Rights Reserved by MedPath